HOME >> BIOLOGY >> NEWS
Clemson researcher receives Komen grant

CLEMSON A Clemson University scientist has received $250,000 to pursue a promising line of research for a way to treat breast cancer. Wen Y. Chen, associate professor in Clemson's department of biological sciences and assistant director of the Oncology Research Institute of Greenville Hospital System, has received funding from the prestigious Susan G. Komen Breast Cancer Foundation in Dallas. He is the first scientist from South Carolina to receive a Komen Foundation grant. Chen will use the money to further his research on stopping breast cancer cells from developing.

"We are excited and grateful for this grant," said Chen. "It signals that we are on the right track. In the past five years, we have focused on developing a potential treatment for breast cancer. With this grant we can move ahead on testing whether the combination approach will significantly improve the existing treatment in an aggressive subtype of breast cancer."

Scientists have learned that human prolactin (PRL), a hormone normally produced in the brain and mainly responsible for mammary gland development and milk production, may be involved in breast cancer development.

"The involvement of PRL in breast cancer is likely due to, in some cases, the fact that mutated breast cells produce PRL as their own survival-growth factor, which keeps most growth signal at "on" position," said Chen. "This self-sustained, vicious growth ability eventually leads to cancer formation."

To "turn off" these growth signals induced by PRL, scientists set out to develop a counteragent -- an antagonist. Working with his colleagues and graduate students at the Oncology Research Institute, Chen has demonstrated that a mutated PRL, called PRL antagonist (G129R), is able to bind specifically to breast cancer cells and block the effect of PRL, inhibiting tumor growth in mice. What's more, the PRL antagonist has synergistic effects with the breast cancer drug Herceptin, which has only 30 percent response
'"/>

Contact: Wen Y. Chen
wenc@clemson.edu
864-455-1457
Clemson University
28-May-2004


Page: 1 2

Related biology news :

1. Clemson University spin-off uses corn to make plastics, provide cleaner air
2. Clemson researcher places hope on pushy photons
3. Clemson University researcher reaches for the stars to prevent osteoporosis
4. Clemson launches S.C. DNA Learning Center
5. Clemson dedicates biotech research complex
6. Breakthrough Clemson research appears in Science
7. Clemson researcher takes part in breakthrough research on insects
8. Clemson researchers find bacteria fighter that does not promote bacterial resistance
9. Clemson researchers identify mental retardation gene
10. Clemson researchers create biosensors to protect nations food and water supplies
11. Clemson-led team makes breakthrough in controlling Bt resistance in pests

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... ... August 05, 2020 , ... Regenative Labs has received approval from the Centers ... making them the first Wharton’s jelly allografts to be assigned a Q code and ... are the first Wharton’s jelly allograft product to be recognized as a 361 HCT/P ...
(Date:7/31/2020)... (PRWEB) , ... July 30, 2020 , ... ... Research (SBIR) Phase II contract awarded by the Joint Science & Technology Office—Chemical ... this project is to develop, optimize, and scale-up a highly efficient mammalian cell ...
(Date:7/22/2020)... Calif. (PRWEB) , ... July 21, 2020 , ... ... driving digital transformation and innovation in technology and compliance, announces a new solution ... device companies must ensure every layer of their technology stack complies with FDA ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... August 11, 2020 , ... The FSHD Society announced ... Dystrophy Clinical Trial Research Network (FSHD CTRN), with consideration of follow-on ... consortium of academic research centers in the United States and Europe with expertise ...
(Date:8/12/2020)... ... August 12, 2020 , ... ... (EMMA International), a global leader in FDA compliance consulting has been named on ... private companies. The list represents a unique look at the most successful companies ...
(Date:8/3/2020)... ... August 03, 2020 , ... ERT, the ... CEO has been named one of the 100 most inspiring individuals in the ... honorees are selected based on how they have inspired their colleagues and affected ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is now offering patients ... million stem cells total, patients may choose which extremities they would like treated. , ... (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is obtained from a ...
Breaking Biology Technology:
Cached News: